Druck Icon

Eckert & Ziegler Increases Stake in Myelo Therapeutics

Berlin, 25 June 2020 – Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has increased its stake in Myelo Therapeutics GmbH (Myelo), a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures. Taking over shares from the local venture capital fund VC Fonds Technologie Berlin, Eckert & Ziegler now directly holds about 15% of the company’s shares. Financial details of the transaction were not disclosed.

Myelo recently completed a financing round that will cover operational expenditures until 2023. The funds are dedicated to complement its Hematopoietic Acute Radiation Syndrome (H-ARS) program and to sustain the clinical expansion of myelo001 as a treatment choice for additional indication such as Radiation-Induced Myelosuppression (RIM).

Myelo was recently awarded a development contract valued up to USD 6 million by the US National Institutes of Health (NIH) to advance its lead candidate myelo001 as a medical countermeasure for the treatment of H-ARS.

About myelo001
Myelo001 is a clinical-stage adjuvant cancer therapy for the treatment of chemotherapy- and radiotherapy-induced myelosuppression. It is delivered as an oral tablet formulation and is stable at room temperature for at least 3 years. Preclinical and clinical studies have shown that myelo001 has both prophylactic and therapeutic efficacy at reducing hematopoietic symptoms caused by radiation and chemotherapy.

About Myelo Therapeutics
Myelo Therapeutics is a pharmaceutical company based in Berlin, Germany, that is developing innovative treatments in areas of high unmet medical needs, such as Chemotherapy-Induced Myelosuppression (CIM), Radiation-Induced Myelosuppression (RIM), and Acute Radiation Syndrome (ARS). For details of the radiation protection pill and the funding commitment of the NHI, see the detailed press release of Myelo Therapeutics: http://www.myelotherapeutics.com/news.html

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG is with more than 800 employees one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.com